Hustling to capture top frontline NSCLC status, Roche scores a ‘breakthrough’ on Alecensa
The FDA has handed Roche bragging rights to its second breakthrough drug designation for Alecensa (alectinib), which is likely to help make the drug’s case …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
